Hybrid closed-loop insulin delivery systems (HCLs) are a new technology for the management of type 1 diabetes. HCLs combine an insulin pump with a continuous glucose monitor (CGM) and a computer program. Together, these use information from the CGM to automatically determine insulin needs throughout the day and keep the user within a pre-determined blood glucose range. They are called hybrid systems because users must still manually account for insulin needs before and after meals.
It has been noted that, across Canada, technologies to manage type 1 diabetes are rapidly evolving. There is a need to understand the place in care, if any, HCLs may have compared with existing technologies.
CADTH will undertake an Optimal Use project to assess the safety and clinical effectiveness, perspectives and experiences of users and health care providers, ethical considerations, and implementation issues of HCLs in people with type 1 diabetes. A review of economic considerations may also be conducted.